Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Veda N Giri, Karen E Knudsen, William K Kelly, Heather H Cheng, Kathleen A Cooney, Michael S Cookson, William Dahut, Scott Weissman, Howard R Soule, Daniel P Petrylak, Adam P Dicker, Saud H AlDubayan, Amanda E Toland, Colin C Pritchard, Curtis A Pettaway, Mary B Daly, James L Mohler, J Kellogg Parsons, Peter R Carroll, Robert Pilarski Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020
PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included ..View full abstract
Awarded by National Institutes of Health Cancer Center Support Grant
Supported by National Institutes of Health Cancer Center Support Grant 5P30CA056036-19, Foundation Medicine, Myriad, Bayer, Clovis Oncology, BioReference Laboratories, Ferring Pharmaceuticals, Philadelphia Father's Day Run, Invitae, AstraZeneca, Janssen Oncology, Roche, UroSeq, Color, OncLive, Physician Education Resource, and MDx Health.